losartan vs captopril | No demonstrated result suggested Cough by 96% (not demonstrated) suggested Adverse events by 41% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
Sudden death | 1.23 [0.95 1.59] | p=1.00 | 0 | 3152 | 1 | ELITE II, | Death from any cause or hospitalization for any reason | 1.03 [0.90 1.17] | p=1.00 | 0 | 3874 | 2 | ELITE, ELITE II, | Cardiovascular death or hospital admission for CHF | no data | death or cardiovascular hospitalization | no data | Cardiovascular death | 0.53 [0.26 1.07] | p=1.00 | 0 | 722 | 1 | ELITE, | hospitalisation for heart failure | 0.93 [0.78 1.10] | p=1.00 | 0 | 3874 | 2 | ELITE, ELITE II, | Hospitalization for any reason | 0.98 [0.86 1.12] | p=1.00 | 0 | 3874 | 2 | ELITE, ELITE II, | | 1.00 [0.62 1.60] | p=1.00 | 0 | 722 | 1 | ELITE, | Hyperkalaemia | 0.35 [0.07 1.75] | p=1.00 | 0 | 722 | 1 | ELITE, | Cough | 0.04 [0.00 0.61] | p=0.04 | 0 | 722 | 1 | ELITE, | Hypotension | 1.68 [0.54 5.19] | p=1.00 | 0 | 722 | 1 | ELITE, | angiodema | 0.15 [0.01 2.92] | p=1.00 | 0 | 722 | 1 | ELITE, | Adverse events | 0.59 [0.44 0.78] | p=0.04 | 0 | 1444 | 2 | ELITE, ELITE, | All cause death | 1.05 [0.88 1.26] | p=1.00 | 0 | 3874 | 2 | ELITE, ELITE II, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs enalapril | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
Sudden death | no data | Death from any cause or hospitalization for any reason | no data | Cardiovascular death or hospital admission for CHF | no data | death or cardiovascular hospitalization | no data | Cardiovascular death | no data | hospitalisation for heart failure | no data | Hospitalization for any reason | no data | | no data | Hyperkalaemia | no data | Cough | no data | Hypotension | no data | angiodema | no data | Adverse events | 1.12 [0.51 2.44] | p=1.00 | 0 | 232 | 2 | Lang et al., Lang et al., | All cause death | 1.18 [0.37 3.76] | p=1.00 | 0 | 564 | 4 | Dickstein et al., Lang et al.,Losartan phase II S,losartan phase II US, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs losartan | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
Sudden death | no data | Death from any cause or hospitalization for any reason | no data | Cardiovascular death or hospital admission for CHF | no data | death or cardiovascular hospitalization | no data | Cardiovascular death | no data | hospitalisation for heart failure | no data | Hospitalization for any reason | no data | | no data | Hyperkalaemia | no data | Cough | no data | Hypotension | no data | angiodema | no data | Adverse events | no data | All cause death | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs placebo | No demonstrated result suggested All cause death by 72% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
Sudden death | no data | Death from any cause or hospitalization for any reason | no data | Cardiovascular death or hospital admission for CHF | no data | death or cardiovascular hospitalization | no data | Cardiovascular death | no data | hospitalisation for heart failure | no data | Hospitalization for any reason | no data | | no data | Hyperkalaemia | no data | Cough | no data | Hypotension | no data | angiodema | no data | Adverse events | no data | All cause death | 0.28 [0.11 0.73] | p=0.04 | 0 | 736 | 2 | Losartan Phase III International,Losartan Phase III U.S., | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan 150mg vs losartan 50mg | No demonstrated result suggested Death from any cause or hospitalization for any reason by 10% (not demonstrated) suggested hospitalisation for heart failure by 13% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
Sudden death | no data | Death from any cause or hospitalization for any reason | 0.90 [0.82 0.99] | p=0.04 | 0 | 3834 | 1 | HEAAL, | Cardiovascular death or hospital admission for CHF | no data | death or cardiovascular hospitalization | 0.92 [0.84 1.00] | p=1.00 | 0 | 3834 | 1 | HEAAL, | Cardiovascular death | no data | hospitalisation for heart failure | 0.87 [0.77 0.99] | p=0.04 | 0 | 3834 | 1 | HEAAL, | Hospitalization for any reason | no data | | 1.33 [0.86 2.06] | p=1.00 | 0 | 3834 | 1 | HEAAL, | Hyperkalaemia | 2.24 [0.69 7.29] | p=1.00 | 0 | 3834 | 1 | HEAAL, | Cough | no data | Hypotension | 1.18 [0.61 2.31] | p=1.00 | 0 | 3834 | 1 | HEAAL, | angiodema | 8.96 [0.48 166.59] | p=1.00 | 0 | 3834 | 1 | HEAAL, | Adverse events | 1.11 [0.87 1.41] | p=1.00 | 0 | 3834 | 1 | HEAAL, | All cause death | 0.94 [0.84 1.05] | p=1.00 | 0 | 3834 | 1 | HEAAL, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan+ACE inhibitor vs ACE inhibitor only | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
Sudden death | no data | Death from any cause or hospitalization for any reason | no data | Cardiovascular death or hospital admission for CHF | no data | death or cardiovascular hospitalization | no data | Cardiovascular death | no data | hospitalisation for heart failure | no data | Hospitalization for any reason | no data | | no data | Hyperkalaemia | no data | Cough | no data | Hypotension | no data | angiodema | no data | Adverse events | no data | All cause death | 0.35 [0.01 9.39] | p=1.00 | 0 | 33 | 1 | Hamroff et al., | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs atenolol | No demonstrated result lung cancer by 141% (harmful effect) suggested cardiovascular events by 14% (not demonstrated) suggested stroke (fatal and non fatal) by 25% (not demonstrated) suggested Diabetes onset by 25% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | 0.86 [0.76 0.98] | p=0.04 | 0 | 9193 | 1 | LIFE, | Cardiovascular death | 0.87 [0.72 1.05] | p=1.00 | 0 | 9193 | 1 | LIFE, | myocardial infarction (fatal and non fatal) | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | stroke (fatal and non fatal) | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | Coronary event | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | cardiac death | no data | cancer related death | 1.03 [0.79 1.34] | p=1.00 | 0 | 9193 | 1 | LIFE, | Heart failure | 0.95 [0.76 1.19] | p=1.00 | 0 | 9193 | 1 | LIFE, | All cause death | 0.89 [0.77 1.02] | p=1.00 | 0 | 9193 | 1 | LIFE, | lung cancer | 2.41 [1.23 4.72] | p=0.04 | 0 | 9193 | 1 | LIFE, | breast cancer | no data | prostate cancer | no data | Cancer | 1.11 [0.95 1.30] | p=1.00 | 0 | 9193 | 1 | LIFE, | Diabetes onset | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Losartan vs Captopril | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
Cardiovascular death | 1.13 [1.00 1.27] | p=1.00 | 0 | 9351 | 3 | ELITE,ELITE-II,OPTIMAAL, | myocardial infarction (fatal and non fatal) | 1.01 [0.88 1.17] | p=1.00 | 0 | 9351 | 3 | ELITE,ELITE-II,OPTIMAAL, | stroke (fatal and non fatal) | 1.11 [0.88 1.39] | p=1.00 | 0 | 9351 | 3 | ELITE,ELITE-II,OPTIMAAL, | All cause death | 1.09 [0.97 1.22] | p=1.00 | 0 | 9351 | 3 | ELITE,ELITE-II,OPTIMAAL, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs placebo | No demonstrated result suggested Heart failure by 29% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | no data | Cardiovascular death | 1.16 [0.84 1.59] | p=1.00 | 0 | 1513 | 1 | RENAAL, | myocardial infarction (fatal and non fatal) | 0.75 [0.51 1.09] | p=1.00 | 0 | 1513 | 1 | RENAAL, | stroke (fatal and non fatal) | 0.97 [0.65 1.47] | p=1.00 | 0 | 1513 | 1 | RENAAL, | Coronary event | no data | cardiac death | no data | cancer related death | no data | Heart failure | 0.71 [0.53 0.95] | p=0.04 | 0 | 1513 | 1 | RENAAL, | All cause death | 1.03 [0.81 1.33] | p=1.00 | 0 | 1513 | 1 | RENAAL, | lung cancer | no data | breast cancer | no data | prostate cancer | no data | Cancer | no data | Diabetes onset | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 2 trials - RENAAL - LIFE
losartan vs atenolol | No demonstrated result lung cancer by 141% (harmful effect) suggested cardiovascular events by 14% (not demonstrated) suggested stroke (fatal and non fatal) by 25% (not demonstrated) suggested Diabetes onset by 25% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | 0.86 [0.76 0.98] | p=0.04 | 0 | 9193 | 1 | LIFE, | Cardiovascular death | 0.87 [0.72 1.05] | p=1.00 | 0 | 9193 | 1 | LIFE, | myocardial infarction (fatal and non fatal) | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | stroke (fatal and non fatal) | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | Coronary event | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | cardiac death | no data | cancer related death | 1.03 [0.79 1.34] | p=1.00 | 0 | 9193 | 1 | LIFE, | Heart failure | 0.95 [0.76 1.19] | p=1.00 | 0 | 9193 | 1 | LIFE, | All cause death | 0.89 [0.77 1.02] | p=1.00 | 0 | 9193 | 1 | LIFE, | lung cancer | 2.41 [1.23 4.72] | p=0.04 | 0 | 9193 | 1 | LIFE, | breast cancer | no data | prostate cancer | no data | Cancer | 1.11 [0.95 1.30] | p=1.00 | 0 | 9193 | 1 | LIFE, | Diabetes onset | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs placebo | No demonstrated result suggested Heart failure by 29% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | no data | Cardiovascular death | 1.16 [0.84 1.59] | p=1.00 | 0 | 1513 | 1 | RENAAL, | myocardial infarction (fatal and non fatal) | 0.75 [0.51 1.09] | p=1.00 | 0 | 1513 | 1 | RENAAL, | stroke (fatal and non fatal) | 0.97 [0.65 1.47] | p=1.00 | 0 | 1513 | 1 | RENAAL, | Coronary event | no data | cardiac death | no data | cancer related death | no data | Heart failure | 0.71 [0.53 0.95] | p=0.04 | 0 | 1513 | 1 | RENAAL, | All cause death | 1.03 [0.81 1.33] | p=1.00 | 0 | 1513 | 1 | RENAAL, | lung cancer | no data | breast cancer | no data | prostate cancer | no data | Cancer | no data | Diabetes onset | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 2 trials - RENAAL - LIFE (diabetic subgroup)
losartan vs atenolol | No demonstrated result suggested cardiovascular events by 24% (not demonstrated) suggested Cardiovascular death by 35% (not demonstrated) suggested All cause death by 39% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | 0.76 [0.58 0.99] | p=0.04 | 0 | 1195 | 1 | LIFE (diabetic subgroup), | Cardiovascular death | 0.65 [0.42 0.99] | p=0.04 | 0 | 1195 | 1 | LIFE (diabetic subgroup), | myocardial infarction (fatal and non fatal) | 0.85 [0.55 1.31] | p=1.00 | 0 | 1195 | 1 | LIFE (diabetic subgroup), | stroke (fatal and non fatal) | 0.82 [0.55 1.20] | p=1.00 | 0 | 1195 | 1 | LIFE (diabetic subgroup), | microvascular events | no data | Non fatal MI | no data | All cause death | 0.61 [0.45 0.83] | p=0.04 | 0 | 1195 | 1 | LIFE (diabetic subgroup), | Non fatal stroke | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs placebo | No demonstrated result suggested microvascular events by 21% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | no data | Cardiovascular death | no data | myocardial infarction (fatal and non fatal) | no data | stroke (fatal and non fatal) | no data | microvascular events | 0.79 [0.66 0.95] | p=0.04 | 0 | 2275 | 1 | RENAAL, | Non fatal MI | no data | All cause death | 1.02 [0.80 1.30] | p=1.00 | 0 | 2275 | 1 | RENAAL, | Non fatal stroke | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with additional risk factor: 1 trials - LIFE
losartan vs atenolol | No demonstrated result lung cancer by 141% (harmful effect) suggested cardiovascular events by 14% (not demonstrated) suggested stroke (fatal and non fatal) by 25% (not demonstrated) suggested Diabetes onset by 25% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | 0.86 [0.76 0.98] | p=0.04 | 0 | 9193 | 1 | LIFE, | Cardiovascular death | 0.87 [0.72 1.05] | p=1.00 | 0 | 9193 | 1 | LIFE, | myocardial infarction (fatal and non fatal) | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | stroke (fatal and non fatal) | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | Coronary event | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | cardiac death | no data | cancer related death | 1.03 [0.79 1.34] | p=1.00 | 0 | 9193 | 1 | LIFE, | Heart failure | 0.95 [0.76 1.19] | p=1.00 | 0 | 9193 | 1 | LIFE, | All cause death | 0.89 [0.77 1.02] | p=1.00 | 0 | 9193 | 1 | LIFE, | lung cancer | 2.41 [1.23 4.72] | p=0.04 | 0 | 9193 | 1 | LIFE, | breast cancer | no data | prostate cancer | no data | Cancer | 1.11 [0.95 1.30] | p=1.00 | 0 | 9193 | 1 | LIFE, | Diabetes onset | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs atenolol | No demonstrated result lung cancer by 141% (harmful effect) suggested cardiovascular events by 14% (not demonstrated) suggested stroke (fatal and non fatal) by 25% (not demonstrated) suggested Diabetes onset by 25% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | 0.86 [0.76 0.98] | p=0.04 | 0 | 9193 | 1 | LIFE, | Cardiovascular death | 0.87 [0.72 1.05] | p=1.00 | 0 | 9193 | 1 | LIFE, | myocardial infarction (fatal and non fatal) | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | stroke (fatal and non fatal) | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | Coronary event | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | cardiac death | no data | cancer related death | 1.03 [0.79 1.34] | p=1.00 | 0 | 9193 | 1 | LIFE, | Heart failure | 0.95 [0.76 1.19] | p=1.00 | 0 | 9193 | 1 | LIFE, | All cause death | 0.89 [0.77 1.02] | p=1.00 | 0 | 9193 | 1 | LIFE, | lung cancer | 2.41 [1.23 4.72] | p=0.04 | 0 | 9193 | 1 | LIFE, | breast cancer | no data | prostate cancer | no data | Cancer | 1.11 [0.95 1.30] | p=1.00 | 0 | 9193 | 1 | LIFE, | Diabetes onset | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs placebo | No demonstrated result suggested Heart failure by 29% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | no data | Cardiovascular death | 1.16 [0.84 1.59] | p=1.00 | 0 | 1513 | 1 | RENAAL, | myocardial infarction (fatal and non fatal) | 0.75 [0.51 1.09] | p=1.00 | 0 | 1513 | 1 | RENAAL, | stroke (fatal and non fatal) | 0.97 [0.65 1.47] | p=1.00 | 0 | 1513 | 1 | RENAAL, | Coronary event | no data | cardiac death | no data | cancer related death | no data | Heart failure | 0.71 [0.53 0.95] | p=0.04 | 0 | 1513 | 1 | RENAAL, | All cause death | 1.03 [0.81 1.33] | p=1.00 | 0 | 1513 | 1 | RENAAL, | lung cancer | no data | breast cancer | no data | prostate cancer | no data | Cancer | no data | Diabetes onset | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs atenolol | No demonstrated result lung cancer by 141% (harmful effect) suggested cardiovascular events by 14% (not demonstrated) suggested stroke (fatal and non fatal) by 25% (not demonstrated) suggested Diabetes onset by 25% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | 0.86 [0.76 0.98] | p=0.04 | 0 | 9193 | 1 | LIFE, | Cardiovascular death | 0.87 [0.72 1.05] | p=1.00 | 0 | 9193 | 1 | LIFE, | myocardial infarction (fatal and non fatal) | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | stroke (fatal and non fatal) | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | Coronary event | 1.05 [0.86 1.29] | p=1.00 | 0 | 9193 | 1 | LIFE, | cardiac death | no data | cancer related death | 1.03 [0.79 1.34] | p=1.00 | 0 | 9193 | 1 | LIFE, | Heart failure | 0.95 [0.76 1.19] | p=1.00 | 0 | 9193 | 1 | LIFE, | All cause death | 0.89 [0.77 1.02] | p=1.00 | 0 | 9193 | 1 | LIFE, | lung cancer | 2.41 [1.23 4.72] | p=0.04 | 0 | 9193 | 1 | LIFE, | breast cancer | no data | prostate cancer | no data | Cancer | 1.11 [0.95 1.30] | p=1.00 | 0 | 9193 | 1 | LIFE, | Diabetes onset | 0.75 [0.63 0.89] | p=0.04 | 0 | 9193 | 1 | LIFE, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
losartan vs placebo | No demonstrated result suggested Heart failure by 29% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
cardiovascular events | no data | Cardiovascular death | 1.16 [0.84 1.59] | p=1.00 | 0 | 1513 | 1 | RENAAL, | myocardial infarction (fatal and non fatal) | 0.75 [0.51 1.09] | p=1.00 | 0 | 1513 | 1 | RENAAL, | stroke (fatal and non fatal) | 0.97 [0.65 1.47] | p=1.00 | 0 | 1513 | 1 | RENAAL, | Coronary event | no data | cardiac death | no data | cancer related death | no data | Heart failure | 0.71 [0.53 0.95] | p=0.04 | 0 | 1513 | 1 | RENAAL, | All cause death | 1.03 [0.81 1.33] | p=1.00 | 0 | 1513 | 1 | RENAAL, | lung cancer | no data | breast cancer | no data | prostate cancer | no data | Cancer | no data | Diabetes onset | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |